Trevi Therapeutics Stock Price, News & Analysis (NASDAQ:TRVI)

Trevi Therapeutics trades on the NASDAQ under the ticker symbol "TRVI."

Trevi Therapeutics Inc (NASDAQ:TRVI) posted its quarterly earnings data on Monday, August, 12th. The company reported ($0.63) earnings per share for the quarter, missing the consensus estimate of ($0.41) by $0.22. View Trevi Therapeutics' Earnings History.

Trevi Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, November 11th 2019. View Earnings Estimates for Trevi Therapeutics.

5 equities research analysts have issued 1 year price targets for Trevi Therapeutics' stock. Their predictions range from $14.00 to $20.00. On average, they expect Trevi Therapeutics' stock price to reach $16.75 in the next year. This suggests a possible upside of 256.4% from the stock's current price. View Analyst Price Targets for Trevi Therapeutics.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Trevi Therapeutics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Trevi Therapeutics.

News headlines about TRVI stock have trended negative recently, InfoTrie Sentiment reports. InfoTrie rates the sentiment of press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Trevi Therapeutics earned a news sentiment score of -2.8 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for Trevi Therapeutics.

Trevi Therapeutics saw a decline in short interest in September. As of September 30th, there was short interest totalling 19,300 shares, a decline of 8.5% from the August 30th total of 21,100 shares. Based on an average daily trading volume, of 13,500 shares, the days-to-cover ratio is presently 1.4 days. Approximately 0.7% of the company's stock are sold short. View Trevi Therapeutics' Current Options Chain.

Some companies that are related to Trevi Therapeutics include CytomX Therapeutics (CTMX), Karuna Therapeutics (KRTX), MediciNova (MNOV), Neptune Wellness Solutions (NEPT), OvaScience (OVAS), Dermira (DERM), Protagonist Therapeutics (PTGX), Corbus Pharmaceuticals (CRBP), Prothena (PRTA), Avid Bioservices (CDMO), CymaBay Therapeutics (CBAY), Theratechnologies (THERF), Ardelyx (ARDX), OptiNose (OPTN) and Atreca (BCEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Trevi Therapeutics investors own include Canopy Growth (CGC), TransEnterix (TRXC), Bicycle Therapeutics (BCYC), Cara Therapeutics (CARA), Restoration Robotics (HAIR), Kalvista Pharmaceuticals (KALV), AbbVie (ABBV), CannTrust (CTST), Olin (OLN) and Alerian MLP ETF (AMLP).

(TRVI) raised $70 million in an IPO on Tuesday, May 7th 2019. The company issued 4,700,000 shares at $14.00-$16.00 per share. SVB Leerink, Stifel and BMO Capital Markets acted as the underwriters for the IPO and Needham & Company was co-manager.

Trevi Therapeutics' lock-up period expires on Monday, November 4th. Trevi Therapeutics had issued 5,500,000 shares in its IPO on May 7th. The total size of the offering was $55,000,000 based on an initial share price of $10.00. After the expiration of Trevi Therapeutics' lock-up period, company insiders and major shareholders will be able to sell their shares of the company.

Trevi Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include NEA Management Company LLC (24.91%). Company insiders that own Trevi Therapeutics stock include Anne Vanlent, Invest A/S Lundbeckfond and Jennifer L Good. View Institutional Ownership Trends for Trevi Therapeutics.

TRVI stock was acquired by a variety of institutional investors in the last quarter, including NEA Management Company LLC. Company insiders that have bought Trevi Therapeutics stock in the last two years include Anne Vanlent, Invest A/S Lundbeckfond and Jennifer L Good. View Insider Buying and Selling for Trevi Therapeutics.

Shares of TRVI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of TRVI stock can currently be purchased for approximately $4.70.

Trevi Therapeutics has a market capitalization of $83.82 million. Trevi Therapeutics employs 15 workers across the globe.View Additional Information About Trevi Therapeutics.

The official website for Trevi Therapeutics is http://www.trevitherapeutics.com/.

Trevi Therapeutics' mailing address is 195 CHURCH STREET 14TH FLOOR, NEW HAVEN CT, 06510. The company can be reached via phone at 203-304-2499 or via email at [email protected]